Please try another search
OliX Pharmaceuticals, Inc. focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company’s products pipeline includes OLX101A for skin scar; OLX201A for idiopathic pulmonary fibrosis; OLX301 for age-related macular degeneration; and OLX301D for subretinal fibrosis. The company has a collaboration agreement with Théa to develop SiRNA therapeutics for ophthalmic diseases; and a research collaboration with PCI Biotech Holding ASA. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Jayakrishna Ambati | - | - | Member of Scientific Advisory Board |
Samir Mitragotri | - | - | Member of Scientific Advisory Board |
Jong-Nam Seo | 59 | - | Director |
Aaron Hakim | - | 2020 | Member of Scientific Advisory Board |
Yury V. Popov | - | 2020 | Member of Scientific Advisory Board |
Demetrios G. Vavvas | - | 2019 | Member of Science & Technology Advisory Board |
Dong-Ki Lee | 49 | - | CEO & Director |
Sung-Hwa Hong | 64 | - | Director |
Hye-Won Chung | - | 2019 | Member of Scientific Advisory Board |
Gordon Jiang | - | 2020 | Member of Scientific Advisory Board |
John Lis | - | - | Member of Scientific Advisory Board |
Sun-Woo Hong | 48 | - | Director |
Tae-Gyeong Kim | 54 | - | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review